Research To Practice | Oncology Videos
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.
Episodes
Androgen Deprivation Therapy for Prostate Cancer — An Interview with Dr Rana R McKay
Featuring an interview with Dr Rana R McKay, including the following topics: Prostate Cancer Working Group (PCWG4) revised terminology (0:00) Cardiovascular effects associated with GnRH agonists versus antagonists; mechanism of action (2:17) Combination therapy using relugolix; factors affecting persistence and adherence to GnRH agents (12:06) Takeaways from the Phase III EMBARK study (19:36) Use
Androgen Deprivation Therapy for Prostate Cancer — An Interview with Dr Rana R McKay (Companion Faculty Lecture)
Featuring a slide presentation and related discussion from Dr Rana R McKay, including the following topics: Overview of the current landscape of prostate cancer (0:00) Mechanism of action of androgen deprivation therapy (ADT) (3:51) Findings from the Phase III HERO study evaluating relugolix versus leuprolide for advanced prostate cancer (7:18) Real-world evidence regarding the use of relugolix (
For Oncology Nurses: Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Proceedings from the 2026 Annual ONS Congress
Featuring perspectives from Dr Alexandra Drakaki, Ms Krisztina Emodi, Dr Terence Friedlander and Ms Margarita Huober, moderated by Dr Friedlander, including the following topics: Introduction: Basic Biology of Nonmetastatic Urothelial Bladder Cancer (UBC) (0:00) Systemic Therapy for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer (MIBC) (13:35) Evolving Approach to Systemic Therap
Targeted Therapies for Non-Small Cell Lung Cancer — Fifth Annual National General Medical Oncology Summit
Featuring perspectives from Dr Lyudmila Bazhenova and Dr Corey J Langer, including the following topics: Introduction (0:00) Therapeutic Approaches Targeting HER2 and RET — Dr Bazhenova (9:09) Therapeutic Approaches Targeting ALK and ROS1 — Dr Langer (31:56) CME information and select publications
HR-Positive Breast Cancer — Fifth Annual National General Medical Oncology Summit
Featuring perspectives from Dr Erika Hamilton, Dr Jane Lowe Meisel, Dr Joyce O'Shaughnessy and Dr Seth Wander, including the following topics: Introduction (0:00) Current and Future Management of HR-Positive, HER2-Negative Localized Breast Cancer — Dr Meisel(2:40) Optimizing First-Line Therapy for Patients with HR-Positive Metastatic Breast Cancer (mBC) — Dr Hamilton (36:57) Current and Future Ro
Acute Myeloid Leukemia — Fifth Annual National General Medical Oncology Summit
Featuring perspectives from Dr Courtney D DiNardo and Dr Harry Paul Erba, including the following topics: Introduction (0:00) Current Management Approaches for FLT3- and IDH-Mutated Acute Myeloid Leukemia (AML) — Dr DiNardo (9:44) Current and Future Role of Menin Inhibitors for Patients with AML — Dr Erba (32:07) CME information and select publications
Desmoid Tumors and Soft Tissue Sarcoma — Fifth Annual National General Medical Oncology Summit
Featuring perspectives from Dr Mrinal Gounder and Dr Richard F Riedel, including the following topics: Introduction (0:00) Desmoid Tumors — Dr Gounder (2:58) Soft Tissue Sarcoma — Dr Riedel (28:29) CME information and select publications
EGFR-Mutated Non-Small Cell Lung Cancer — Fifth Annual National General Medical Oncology Summit
Featuring perspectives from Dr Jonathan Goldman and Dr Zofia Piotrowska, including the following topics: Introduction (0:00) Current Management of Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) — Dr Goldman (0:38) Nonmetastatic EGFR-Mutated NSCLC, Exon 20 Insertion Mutations and Novel Agents — Dr Piotrowska (33:20) CME information and select publications
Metastatic Triple-Negative Breast Cancer — What Clinicians Want to Know
Featuring perspectives from Dr Kevin Punie and Dr Tiffany A Traina, including the following topics: Introduction: Where We Are; Where We're Heading (0:00) First-Line Treatment of BRCA Wild-Type Disease (9:14) First-Line Treatment of BRCA-Mutant Disease (38:48) Novel Approaches (47:49) CME information and select publications
Urothelial Bladder Cancer | Thomas Powles, MBBS, MRCP, MD
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Non-Muscle-Invasive and Muscle-Invasive Urothelial Bladder Cancer | Faculty Presentation 2: Muscle-Invasive Bladder Cancer — Thomas Powles, MBBS, MRCP, MD CME information and select publications
Urothelial Bladder Cancer | Ashish M Kamat, MD, MBBS
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Non-Muscle-Invasive and Muscle-Invasive Urothelial Bladder Cancer | Faculty Presentation 1: Non-Muscle-Invasive Bladder Cancer — Ashish M Kamat, MD, MBBS CME information and select publications
Urothelial Bladder Cancer — Year in Review Series on Relevant New Datasets and Advances
Featuring perspectives from Dr Ashish M Kamat and Prof Thomas Powles, including the following topics: Introduction: Life After Radical Cystectomy (0:00) Muscle-Invasive Bladder Cancer — Prof Powles (9:15) Non-Muscle-Invasive Bladder Cancer — Dr Kamat (37:49) CME information and select publications
For Oncology Nurses: Endometrial Cancer — Proceedings from the 2026 Annual ONS Congress
Featuring perspectives from Dr Dana M Chase, Ms Sarah Karpen, Dr J Alejandro Rauh-Hain and Ms Jaclyn Shaver, moderated by Dr Chase, including the following topics: Introduction: Biology of Endometrial Cancer (EC) (0:00) First-Line Therapy for Advanced or Recurrent EC (14:15) Potential Benefits of PARP Inhibition Combined with Immunotherapy in Advanced EC (35:13) Role of Lenvatinib/Pembrolizumab i
Myelofibrosis and Systemic Mastocytosis — Fifth Annual National General Medical Oncology Summit
Featuring perspectives from Dr Anthony M Hunter and Dr Abdulraheem Yacoub, including the following topics: Introduction (0:00) Systemic Mastocytosis — Dr Hunter (9:33) Myelofibrosis — Dr Yacoub (29:40) CME information and select publications
Prostate Cancer — Fifth Annual National General Medical Oncology Summit
Featuring perspectives from Dr Neeraj Agarwal and Dr Alan H Bryce, including the following topics: Introduction (0:00) Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer — Dr Bryce (2:41) Other Available and Emerging Therapeutic Approaches — Dr Agarwal (35:16) CME information and select publications
HER2-Positive Breast Cancer — Fifth Annual National General Medical Oncology Summit
Featuring perspectives from Dr Erika Hamilton and Dr Shanu Modi, including the following topics: Introduction (0:00) Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Dr Modi (0:58) Contemporary Management of HER2-Positive Metastatic Breast Cancer — Dr Hamilton (25:51) CME information and select publications
Colorectal Cancer — Fifth Annual National General Medical Oncology Summit
Featuring perspectives from Dr Kristen K Ciombor and Dr John Strickler, including the following topics: Introduction (0:00) Current and Future Role of Immune Checkpoint Inhibitors in the Management of Colorectal Cancer (CRC) — Dr Ciombor (3:58) Other Recent Advances in CRC Management — Dr Strickler (32:57) CME information and select publications
Triple-Negative Breast Cancer — Fifth Annual National General Medical Oncology Summit
Featuring perspectives from Dr Adam M Brufsky and Dr Kevin Kalinsky, including the following topics: Introduction (0:00) Current and Future Role of TROP2-Directed Antibody-Drug Conjugates in Therapy for Triple-Negative Breast Cancer (TNBC) — Dr Brufsky (5:08) Established Treatment Paradigm for Localized and Metastatic TNBC — Dr Kalinsky (35:20) CME information and select publications
Desmoid Tumors — Microlearning Activity 4 with Prof Bernd Kasper
Featuring an interview with Prof Bernd Kasper, including the following topics: Case: A woman in her early 30s develops a progressing desmoid tumor in her abdomen during pregnancy(0:00) Case: A woman in her late 30s with a painful small desmoid tumor in her rectus abdominus undergoes cryoablation (8:04) Case: A woman in her late teens with recurrent desmoid tumors in her right thigh undergoes mult
Ovarian Cancer — Fifth Annual National General Medical Oncology Summit
Featuring perspectives from Dr Deborah K Armstrong and Dr David M O'Malley, including the following topics: Introduction (0:00) PARP Inhibitors and Strategies Targeting Folate Receptor Alpha in Advanced Ovarian Cancer — Dr Armstrong (4:37) Other Novel Agents and Strategies for the Treatment of Advanced Ovarian Cancer — Dr O'Malley (35:18) CME information and select publications
Gastroesophageal Cancers — Fifth Annual National General Medical Oncology Summit
Featuring perspectives from Dr Yelena Y Janjigian and Dr Samuel J Klempner, including the following topics: Introduction (0:00) Role of Anti-PD-1/PD-L1- and CLDN18.2-Directed Antibodies in the Management of Gastroesophageal Cancers — Dr Klempner (5:52) Management of HER2-Positive Gastroesophageal Cancers — Dr Janjigian (28:20) CME information and select publications
Multiple Myeloma — Fifth Annual National General Medical Oncology Summit
Featuring perspectives from Dr Hans Lee and Dr Noopur Raje, including the following topics: Introduction (0:00) Integrating Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies into the Management of Relapsed/Refractory Multiple Myeloma (R/R MM) — Dr Raje (4:30) Antibody-Drug Conjugates and Other Emerging Therapies for R/R MM — Dr Lee (28:33) CME information and select publications
First-Line and Maintenance Therapy for Patients with Extensive-Stage Small Cell Lung Cancer — An Interview with Prof Martin Reck (Companion Faculty Lecture)
Featuring a slide presentation and related discussion from Prof Martin Reck, including the following topics: Overview of small cell lung cancer (SCLC) (0:00) First-line chemoimmunotherapy for extensive-stage SCLC (ES-SCLC) (3:50) Lurbinectedin as first-line maintenance therapy for ES-SCLC (12:36) Case: A man in his early 60s with ES-SCLC receives first-line atezolizumab/carboplatin/etoposide foll
First-Line and Maintenance Therapy for Patients with Extensive-Stage Small Cell Lung Cancer — An Interview with Prof Martin Reck
Featuring an interview with Prof Martin Reck, including the following topics: Case: A woman in her mid 70s with extensive-stage small cell lung cancer (ES-SCLC) experiences a strong response to first-line chemoimmunotherapy and maintenance lurbinectedin/atezolizumab (0:00) Biology of small cell lung cancer and pharmacodynamics of systemic treatment (3:25) Considerations with maintenance therapy f
Urothelial Bladder Cancer — Fifth Annual National General Medical Oncology Summit
Featuring perspectives from Dr Terence Friedlander and Dr Daniel P Petrylak, including the following topics: Introduction (0:00) Role of Immunotherapeutic Strategies in the Management of Nonmetastatic Urothelial Bladder Cancer (UBC); Emerging Utility of Circulating Tumor DNA Evaluation — Dr Friedlander (3:53) Other Novel Agents and Strategies for Nonmetastatic and Metastatic UBC — Dr Petrylak (26
HER2-Positive Gynecologic Cancers — Proceedings from a Session Held During the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancer
Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topics: Introduction (0:00) Strategies to Identify Patients with HER2-Positive Gynecologic Cancers — Dr Liu (2:52) Available Data with and Practical Application of HER2-Targeted Therapy in Advanced Gynecologic Cancers — Dr Slomovitz (25:16) Identification and
Chronic Lymphocytic Leukemia — Fifth Annual National General Medical Oncology Summit
Featuring perspectives from Dr John N Allan and Dr Adam Kittai, including the following topics: Introduction (0:00) Current Management of Newly Diagnosed Chronic Lymphocytic Leukemia — Dr Allan (8:47) Noncovalent Bruton Tyrosine Kinase Inhibitors and Other Novel Strategies — Dr Kittai (38:14) CME information and select publications
Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2026 American Urological Association Annual Meeting
Featuring perspectives from Dr Neeraj Agarwal, Dr Elisabeth I Heath, Dr Daniel P Petrylak, Dr Fred Saad and Dr Neal D Shore, moderated by Dr Heath, including the following topics: Introduction (0:00) Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Shore (2:12) Current Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Petrylak (27:54) Current and Future Role of
Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Fifth Annual National General Medical Oncology Summit
Featuring perspectives from Dr Manali Kamdar, Dr Krish Patel and Dr Gilles Salles, including the following topics: Introduction (0:00) Antibody-Drug Conjugates and Other Novel Strategies for the Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Prof Salles (7:05) Current and Future Role of Monoclonal and Bispecific Antibodies in the Management of DLBCL — Dr Patel (26:21) Chimeric Antigen Rece
Pancreatic Cancer — Fifth Annual National General Medical Oncology Summit
Featuring perspectives from Dr Eileen M O'Reilly and Dr Philip A Philip, including the following topics: Introduction (0:00) Optimal Incorporation of Chemotherapy into the Management of Advanced Pancreatic Cancer — Dr Philip (7:27) Other Available and Emerging Novel Approaches for Pancreatic Cancer — Dr O'Reilly (28:05) CME information and select publications
Localized Renal Cell Carcinoma — Proceedings from a Session Held in Conjunction with the 2026 American Urological Association Annual Meeting
Featuring perspectives from Dr Thomas E Hutson, Dr Erik A Singer and Dr Ulka Vaishampayan, moderated by Dr Hutson, including the following topics: Introduction (0:00) Current Indications for Adjuvant Immune Checkpoint Inhibitor Therapy in the Management of Renal Cell Carcinoma (RCC) — Dr Singer (2:32) Potential Role of Hypoxia-Inducible Factor-2 Alpha Inhibitors as a Component of Adjuvant Treatme
HR-Positive Metastatic Breast Cancer — A Discussion and Debate on First- and Second-Line Therapy
Featuring perspectives from Dr Sara A Hurvitz and Dr Virginia Kaklamani, including the following topics: Introduction: Which Biomarkers and When (0:00) Optimizing First-Line Therapy for Patients with Hormone Receptor (HR)-Positive Metastatic Breast Cancer (mBC) (5:31) SERENA-6 Trial (19:44) Inavolisib (23:08) Management of HR-Positive mBC Progressing on a CDK4/6 Inhibitor and Endocrine Therapy (3
Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
Featuring perspectives from Dr Christine L Hann and Dr Jacob Sands, including the following topics: Introduction: Biopharmacology of Small Cell Lung Cancer — "Wildfire sparked in dry grass" (0:00) Limited-Stage Disease (9:22) Extensive-Stage Disease (16:23) Paraneoplastic Syndromes — Lambert-Eaton Myasthenic Syndrome (23:54) Bispecific T-Cell Engagers — Tarlatamab (30:00) Antibody-Drug Conjugates
Small Cell Lung Cancer | Jacob Sands, MD
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Small Cell Lung Cancer | Faculty Presentation 1: Limited-Stage Small Cell Lung Cancer (SCLC); First-Line and Maintenance Therapy for Extensive-Stage SCLC — Jacob Sands, MD CME information and select publications
Small Cell Lung Cancer | Christine L Hann, MD, PhD
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Small Cell Lung Cancer | Faculty Presentation 2: Management of Relapsed/Refractory SCLC; Promising Investigational Agents and Strategies — Christine L Hann, MD, PhD CME information and select publications
Genitourinary Cancers — 5-Minute Journal Club Issue 2 with Professor Thomas Powles: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
Featuring perspectives from Prof Thomas Powles, including the following topics: Circulating tumor DNA (ctDNA) analyses with adjuvant nivolumab for MIBC in the CheckMate 274 study (0:00) Use of ctDNA to guide response-adapted bladder preservation for patients with MIBC (2:27) ctDNA response-adapted treatment de-escalation for patients with metastatic urothelial carcinoma: The CT-READ trial (10:26)
Antibody-Drug Conjugates in Gynecologic Cancers — Proceedings from a Session Held During the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancer
Featuring perspectives from Prof Ramez Eskander and Dr Bradley Monk, moderated by Dr Kathleen Moore, including the following topics: Introduction (0:00) Advances in Human Cadherin-6-Targeted Antibody-Drug Conjugates (ADCs) in Ovarian and Other Gynecologic Cancers — Dr Moore (1:30) Leveraging TROP2-Directed ADCs in Advanced Gynecologic Cancers — Prof Eskander (35:39) Tolerability and Other Practic
Desmoid Tumors — Microlearning Activity 3 with Prof Bernd Kasper
Interview conducted with Prof Bernd Kasper on March 5, 2026, by Dr Neil Love, including the following topics: Current management of desmoid tumors: A review from the Desmoid Tumor Working Group (0:00) Long-term nirogacestat treatment in adult patients with desmoid tumors: Updated efficacy and safety from the Phase III DeFi trial (8:26) Phase IV trial of nirogacestat in adult premenopausal women w
Colorectal Cancer — Year in Review Series on Relevant New Datasets and Advances
Proceedings from a webinar on April 16, 2026, moderated by Dr Neil Love, including the following topics: Introduction: Research To Practice Paper of the Year! (0:00) Checkpoint Inhibitors for Localized Microsatellite Instability-High Tumors (11:12) Circulating Tumor DNA Assays (21:58) Checkpoint Inhibitors for Metastatic Disease (38:32) CME information and select publications
Colorectal Cancer | Arvind Dasari, MD, MS
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Colorectal Cancer | Faculty Presentation 2: Optimizing the Care of Patients with Nonmetastatic Colorectal Cancer (CRC) — Arvind Dasari, MD, MS CME information and select publications
Colorectal Cancer | Anwaar Saeed, MD
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Colorectal Cancer | Faculty Presentation 1: Recent Advances in the Management of Metastatic CRC (mCRC) — Anwaar Saeed, MD CME information and select publications
Genitourinary Cancers — 5-Minute Journal Club Issue 1 with Professor Thomas Powles: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
Interview conducted on March 11, 2026, by Dr Neil Love, including the following topics: Circulating tumor DNA (ctDNA)-guided adjuvant therapy with atezolizumab for muscle-invasive bladder cancer (MIBC) (0:00) Use of ctDNA in guiding systemic treatment selection for patients with urothelial bladder cancer (10:03) ctDNA analyses with perioperative durvalumab for MIBC in the Phase III NIAGARA study
Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and Advances
Proceedings from a webinar on March 11, 2026, moderated by Dr Neil Love, including the following topics: Introduction: I think I missed that day in med school (BTK biology) (0:00) First-Line Treatment (11:40) Relapsed/Refractory Disease (46:35) CME information and select publications
Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia | Jennifer R Brown MD, PhD
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia | Faculty Presentation 2: Emerging BTK Inhibitor-Based Combination Approaches in CLL — Jennifer R Brown MD, PhD CME information and select publications
Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia | Wojciech Jurczak MD, PhD
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia | Faculty Presentation 1: Role of Bruton Tyrosine Kinase (BTK) Inhibitors in Newly Diagnosed and Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) — Wojciech Jurczak MD, PhD CME information and select publications
Ovarian Cancer — Proceedings from a Session Held During the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancer
Proceedings from a live event on April 12, 2026, held during the SGO 2026 Annual Meeting on Women's Cancer and moderated by Dr Shannon Westin, including the following topics: Introduction (0:00) Current Role of PARP Inhibitors for Advanced Ovarian Cancer — Prof Colombo (1:59) Strategies Targeting Folate Receptor Alpha for Advanced Ovarian Cancer — Dr Westin (25:53) Other Novel Agents and Strategi
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 4: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Featuring proceedings from a live event on January 9, 2026, held adjunct to the 2026 ASCO Gastrointestinal Cancers Symposium and moderated by Dr Samuel J Klempner, including the following topics: Treatment approach for metastatic HER2-negative, claudin 18.2-positive, microsatellite instability-high gastroesophageal (GE) cancer (0:00) Duration of chemotherapy for patients with advanced GE cancers
PARP Inhibitors for Patients with Hormone-Sensitive and Castration-Resistant Metastatic Prostate Cancer — An Interview with Dr Wassim Abida
Featuring an interview with Dr Wassim Abida, including the following topics: Comparing the clinical relevance of BRCA1 and BRCA2 mutations in prostate cancer (0:00) Relevance and interpretation of LOH (loss of heterozygosity) scores (4:37) Incidence and clinical relevance of PALB2 mutations; role of genetic counseling in the care of patients with prostate cancer (9:33) Key considerations surround
PARP Inhibitors for Patients with Hormone-Sensitive and Castration-Resistant Metastatic Prostate Cancer — An Interview with Dr Wassim Abida (Companion Faculty Lecture)
Featuring a slide presentation and related discussion from Dr Wassim Abida, including the following topics: Clinical implications of homologous recombination repair gene alterations and biological rationale for the use of PARP inhibitors (0:00) Key clinical studies leading to FDA approvals of PARP inhibitors as monotherapy (5:01) Biological rationale for combining PARP inhibitors with androgen re
Immunotherapy for Endometrial Cancer — Proceedings from a Session Held During the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancer
Proceedings from a live event on April 11, 2026, held during the 2026 SGO Annual Meeting on Women's Cancer and moderated by Dr Ritu Salani, including the following topics: Biology of Advanced Endometrial Cancer (EC); Optimal Approach to Biomarker Assessment in Patients with Newly Diagnosed Disease — Dr Backes (0:00) Current Up-Front Chemoimmunotherapeutic Approaches for Advanced EC — Dr Powell (2
Oncology Nursing Update: Nonmelanoma Skin Cancers — An Interview with Dr Nikhil Khushalani
Featuring an interview with Dr Nikhil I Khushalani, including the following topics: Overview of nonmelanoma skin cancers (0:00) Systemic therapy for nonmelanoma skin cancers (12:11) Immune checkpoint inhibitors for special patient populations (20:30) Hedgehog inhibitors for basal cell carcinoma (32:14) New developments in therapy for nonmelanoma skin cancers (38:52) Case: A man in his early 70s w
Localized Colorectal Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics: Role of circulating tumor DNA (ctDNA) testing in the escalation of treatment for Stage II and deescalation for Stage III colon cancer (0:00) Impact of timing on the clinical relevance of ctDNA minimal residual disease test results in localized colorectal
Oral SERDs for Breast Cancer | Aditya Bardia, MD, MPH
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Oral SERDs for Breast Cancer | Faculty Presentation 1: Appropriate Identification of Candidates for and Practical Implementation of Oral Selective Estrogen Receptor Degraders (SERDs) for Progressive HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Aditya Bardia, MD, MPH CME information
Oral SERDs for Breast Cancer | Erica Mayer, MD, MPH, FASCO
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Oral SERDs for Breast Cancer | Faculty Presentation 2: Future Directions in the Use of Oral SERDs for HR-Positive, HER2-Negative BC — Erica Mayer, MD, MPH, FASCO CME information and select publications
Oral SERDs for Breast Cancer — Year in Review Series on Relevant New Datasets and Advances
Featuring perspectives from Dr Aditya Bardia and Dr Erica Mayer, including the following topics: Introduction: How Selective Estrogen Receptor Degraders (SERDs) Work (0:00) Second-Line Treatment for Metastatic Breast Cancer (16:01) First-Line Therapy for Metastatic Disease (33:19) Adjuvant Therapy (35:26) Toxicity, Quality of Life (47:59) New Directions (55:22) CME information and select publica
EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
Featuring perspectives from Dr Suresh S Ramalingam and Dr Helena Yu, including the following topics: Introduction: Genomics of EGFR (and HER2) (0:00) Metastatic Disease (9:30) Localized Disease (30:22) EGFR Exon 20 Insertion Mutations (46:57) New Agents (54:20) CME information and select publications
EGFR-Mutant Non-Small Cell Lung Cancer | Suresh S Ramalingam, MD
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in EGFR-Mutant Non-Small Cell Lung Cancer | Faculty Presentation 2: Other Relevant Topics in EGFR-Mutant NSCLC (eg, Nonmetastatic Disease, Exon 20 Insertion Mutations, Novel Agents) — Suresh S Ramalingam, MD CME information and select publications
EGFR-Mutant Non-Small Cell Lung Cancer | Helena Yu, MD
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in EGFR-Mutant Non-Small Cell Lung Cancer | Faculty Presentation 1: Management of Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) — Helena Yu, MD CME information and select publications
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics: Role of PD-L1 status, tumor histology and pulmonary disease in selection of immune checkpoint inhibition as up-front therapy (0:00) Impact of metastatic site and autoimmune disease on clinical decision-making in the use of immune che
Prostate Cancer — Year in Review Series on Relevant New Datasets and Advances
Featuring perspectives from Dr Andrew J Armstrong and Dr Scott T Tagawa, including the following topics: Introduction: Evolution of the Prostate Cancer Model; Prostate Cancer Working Group 4 (PCWG4) (0:00) Hormonal Therapy (5:48) Chemotherapy (Docetaxel) (26:38) PARP Inhibition (29:49) Radioligand Therapy (36:56) New Agents (43:37) CME information and select publications
Prostate Cancer | Scott T Tagawa, MD, MS
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Prostate Cancer | Faculty Presentation 2: Other Available and Emerging Therapeutic Approaches — Scott T Tagawa, MD, MS CME information and select publications
Prostate Cancer | Andrew J Armstrong, MD, ScM
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Prostate Cancer | Faculty Presentation 1: Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer — Andrew J Armstrong, MD, ScM CME information and select publications
Menin Inhibitors in Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances
Featuring perspectives from Dr Amir Fathi and Dr Eunice S Wang, including the following topics: Introduction: Overview — Biopharmacologic Considerations (0:00) Menin Inhibitor Monotherapy (21:51) Differentiation Syndrome (36:12) Menin Inhibitor Combination Approaches (45:15) Future Directions (49:59) PARADIGM — Randomized Phase II Trial (53:24) CME information and select publications
Menin Inhibitors in Acute Myeloid Leukemia | Eunice S Wang, MD
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Menin Inhibitors in Acute Myeloid Leukemia | Faculty Presentation 1: Biology Underlying the Utility of Menin Inhibitors in Acute Leukemias: Use of These Agents as Monotherapy — Eunice S Wang, MD CME information and select publications
Menin Inhibitors in Acute Myeloid Leukemia | Amir Fathi, MD
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Menin Inhibitors in Acute Myeloid Leukemia | Faculty Presentation 2: Potential Role of Menin Inhibitors as a Component of Combination Therapy — Amir Fathi, MD CME information and select publications
Lung Cancer — 5-Minute Journal Club with Dr Natalie Vokes: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
Featuring an interview with Dr Natalie Vokes, including the following topics: Perioperative minimal residual disease (MRD) detected by circulating tumor DNA (ctDNA) testing in patients with lung cancer (0:00) Ohara S et al. Clinical significance of perioperative MRD detected by ctDNA in patients with lung cancer with a long follow-up data: An exploratory study. JTO Clin Res Rep 2024;6(3):100762.
HR-Positive Metastatic Breast Cancer — An Interview with Dr Seth Wander on Biomarker Assessment and Related Treatment Decision-Making
Featuring an interview with Dr Seth Wander, including the following topics: Deciding between liquid and tissue biopsy; role of epigenetics in oncogenic events (0:00) Potential role of thymidine kinase testing in monitoring response to therapy (4:56) Interpretation of next-generation sequencing testing; use of targeted therapy (10:59) Phase III lidERA Breast Cancer trial and its implications for t
HR-Positive Metastatic Breast Cancer — An Interview with Dr Seth Wander on Biomarker Assessment and Related Treatment Decision-Making (Companion Faculty Lecture)
Featuring a slide presentation and related discussion from Dr Seth Wander, including the following topics: Biological impact of clinically relevant biomarkers (eg, ESR1 mutations, PIK3CA/AKT1/PTEN alterations) (0:00) Methodologies for biomarker assessment in clinical practice: Tissue versus liquid biopsy (5:21) Methodologies for biomarker assessment in clinical practice: Novel platforms (13:56) A
Metastatic Bladder Cancer — Rapid Case Review Issue 4
Featuring patient case presentations by Dr Jacqueline T Brown and Dr Nazli Dizman, with commentary from Dr Matthew Milowsky, including the following topics: Case: A woman in her early 60s with muscle-invasive bladder cancer experiences disease progression with lung metastasis after surgery and receives enfortumab vedotin (EV)/pembrolizumab (0:00) Case: A man in his mid 70s with metastatic urothel
ER-Positive, HER2-Positive Metastatic Breast Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy
Featuring perspectives from Dr Virginia F Borges and Dr Ian E Krop, including the following topics: Introduction: Biology of "Triple-Positive" Breast Cancer; Implications for Therapeutic Development (0:00) Cases from the GMO Survey (13:01) First-Line Therapy for Metastatic HER2-Positive Disease (20:01) Maintenance Therapy for HR-Positive, HER2-Positive Disease (30:03) Maintenance Therapy for HR-N
Localized Colorectal Cancer — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics: Adjuvant treatment planning for Stage II or III microsatellite instability-high colon cancer (0:00) Roles of circulating tumor DNA (ctDNA), POLE mutations and advanced age in adjuvant treatment planning (6:08) Role of ctDNA in adjuvant treatment planning
CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson
Featuring perspectives from Dr Paul G Richardson, including the following topics: EXCALIBER-RRMM: A Phase III trial of iberdomide, daratumumab and dexamethasone for relapsed/refractory multiple myeloma (0:00) Lonial S et al. EXCALIBER-RRMM: A phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. Future Oncol 2025;21(14):1761-9. Abstract Phase I
HER2-Positive Gastrointestinal Cancers — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Featuring perspectives from Dr Haley Ellis, Prof Eric Van Cutsem and Dr Zev Wainberg, moderated by Dr Lionel A Kankeu Fonkoua, including the following topics: Gastroesophageal cancer (0:00) Recurrent colorectal cancer (5:43) Colorectal cancer with brain metastases (9:59) CME information and select publications
Desmoid Tumors — Microlearning Activity 2 with Dr Ravin Ratan
Featuring an interview with Dr Ravin Ratan, including the following topics: Case: A woman in her early 40s who develops intense nausea and vomiting and is diagnosed with a pelvic desmoid tumor elects surveillance and experiences spontaneous regression of the tumor (0:00) Case: A woman in her late 30s with a painful desmoid tumor in the right pelvic wall receives cryoablation because of concerns a
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics: Older patient with metastatic claudin 18.2-positive gastroesophageal (GE) cancer (0:00) Management of nausea and vomiting with zolbetuximab for GE cancer (9:37) Younger patient with metastatic claudin 18.2-positive, PD-L1-positive GE
Nonmelanoma Skin Cancers — A Roundtable Discussion on the Multidisciplinary Management of Cutaneous Squamous Cell and Basal Cell Carcinomas
Featuring slide presentations and related discussion from Dr Nikhil I Khushalani, Dr Soo J Park, Dr Vishal Anil Patel and Dr Evan Wuthrick, including the following topics: Introduction (0:00) Current Management of Localized, Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) (9:55) Case: A man in his early 70s with cSCC who previously underwent surgery and adjuvant therapy (
Immune Thrombocytopenia — Microlearning Activity 4 with Dr Hanny Al-Samkari: ASH 2025 Review
Featuring an interview with Dr Hanny Al-Samkari, including the following topics: Case: A man in his early 40s with chronic immune thrombocytopenia (ITP) receives romiplostim with rituximab — Bhavana (Tina) Bhatnagar, DO (0:00) Case: A woman in her early 80s with metastatic adenocarcinoma of the lung responds to carboplatin/pemetrexed/pembrolizumab but after 14 months of maintenance pembrolizumab
AKT Inhibition in Prostate Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium
Featuring perspectives from Prof Karim Fizazi and Dr Daniel George, moderated by Dr Elisabeth I Heath, including the following topics: Introduction (0:00) Clinical Implications of and Appropriate Strategies to Identify PTEN Deficiency in Prostate Cancer — Dr George (3:25) Targeting AKT in Metastatic Prostate Cancer — Prof Fizazi (32:54) Tolerability and Other Practical Considerations with Capivas
Diabetology in Breast Cancer — Managing Hyperglycemia in Patients with Breast Cancer Receiving Agents Targeting the PI3K/AKT/PTEN Pathway
Featuring perspectives from Ms Jamie Carroll, Prof Giuseppe Curigliano, Dr Marie E McDonnell and Dr Hope S Rugo, including the following topics: Introduction: Use of On-Body Glucose Monitoring Devices (0:00) Overview of Breast Cancer and Diabetes (9:39) PI3K/AKT/mTOR Pathway and Glucose Metabolism (19:28) Case Presentations — Part 1 (26:02) Current Data with Alpelisib, Capivasertib and Inavolisib
Metastatic Bladder Cancer — Rapid Case Review Issue 3
Featuring patient case presentations by Dr Jacqueline T Brown and Dr Nazli Dizman, with commentary from Dr Matthew Milowsky, including the following topics: Case: A man in his mid 50s with metastatic recurrence of urothelial bladder cancer (UBC) after neoadjuvant cisplatin/gemcitabine receives first-line enfortumab vedotin (EV)/pembrolizumab (0:00) Case: A man in his early 50s with muscle-invasiv
